Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile

NEW YORK, Jan. 11, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Sanofi-Aventis: PharmaVitae Profile

http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Sanofi-Aventis's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Sanofi-Aventis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Sanofi-Aventis's performance against key rivals in the prescription pharmaceutical sector.* Analyse the positioning of the company as a diversified healthcare player with an enhanced focus on the vaccine, generic and consumer markets.* Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth.

To order this report:

: Sanofi-Aventis: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.